Bloomberg | March 9, 2024
The US shortage of Pfizer Inc.’s drug that’s the optimal treatment for syphilis will likely extend at least into October as the country faces skyrocketing rates of the potentially deadly disease.
While Pfizer had anticipated supplies of Bicillin L-A would normalize by the end of June, the expected shortfall has been extended into the final three months of the year, according to an update of a Food and Drug Administration website Friday. It’s unclear whether Pfizer expects a normal supply toward the beginning or end of the fourth quarter. The company didn’t immediately provide comment.
US rates of syphilis, a sexually transmitted bacterial infection, have been increasing for years amid declining public health funding, increased substance abuse and riskier sexual behavior.
I think if we brought morals back there would be no reason to worry about STDs.